Oneness Biotech Co.,LTD receives a China patent
on antagonistic PDL1 aptamers.
Date of events
2022/05/26
To which item it meets
paragraph 53
Statement
1.Date of occurrence of the event:2022/05/26
2.Company name:ONENESS BIOTECH CO., LTD.
3.Relationship to the Company (please enter "head office" or
"subsidiaries"):head office
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:The Company has been informed by the patent agency that
the antagonistic PDL1 aptamer has been granted a China patent titled
"ANTAGONISTIC PDL1 APTAMERS AND THEIR APPLICATIONS IN CANCER THERAPY" under
patent number 4620171.
6.Countermeasures:None
7.Any other matters that need to be specified:
(1)This patent covers the aptamers that bind to and antagonize PDL1 and uses
thereof in enhancing immune activity(e.g.,promoting T cell proliferation),
treating cancer, and/or infectious diseases such as infections caused by
enterovirus, HBV or HCV.
(2)This patent is owned by National Taiwan University and Academia Sinica.
Oneness Biotech Co.,LTD has been exclusively authorized to use this patent
and to manufacture, use and sell the products of this invention.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Oneness Biotech Co Ltd. published this content on 26 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 May 2022 12:20:26 UTC.
ONENESS BIOTECH CO., LTD. is a Taiwan-based company principally engaged in the research, development, production and sales of health products. The Company's main products include health supplies, health food and healthy food. The Company is also involved in the development of new drugs for the treatment of wound healing in chronic diabetic foot ulcers, as well as the development of new anticancer drugs. The Company distributes its products in domestic market.